Cover Image
市場調查報告書

大腸癌治療藥產業、市場:治療、R&D 及預測 2015-2025年

Colorectal Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2015-2025

出版商 Visiongain Ltd 商品編碼 345210
出版日期 內容資訊 英文 114 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
大腸癌治療藥產業、市場:治療、R&D 及預測 2015-2025年 Colorectal Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2015-2025
出版日期: 2015年11月16日 內容資訊: 英文 114 Pages
簡介

本報告提供全球大腸癌治療藥市場現況與展望調查分析、市場概要、全球及各地區的收益預測、主要治療藥的收益預測、主要企業簡介、治療藥開發平台、R&D趨勢、專家的見解等彙整資料,為您概述為以下內容。

第1章 調查概要

第2章 大腸癌、治療的簡介

  • 大腸癌的病理學
  • 大腸癌的流行病學
    • 發病率:隨老齡化增加
    • 死亡率:癌症死亡原因的第4名
    • 存活率:分期應對
  • 診斷:優點與限制
  • 治療和分期
    • 治療的選項
    • 大腸癌的分期
    • 階段應對的治療

第3章 全球大腸癌治療藥市場

  • 全球大腸癌治療藥市場預測
  • 地區的大腸癌治療藥市場預測
    • 美國
    • 日本
    • EU
    • 亞太地區
    • 其他

第4章 主要大腸癌治療藥:收益預測

  • Avastin (Roche)
  • 爾必得舒(Erbitux) (BMS/Merck KGaA)
  • Xeloda (Roche)
  • Vectibix (Amgen)
  • Eloxatin (Sanofi)
  • Zaltrap (Sanofi/Regeneron 共同開發)
  • Stivarga (Bayer)
  • TS-1 (大鵬藥品工業)
  • Cyramza (Eli Lilly)

第5章 新的治療藥

  • Lonsurf (大鵬藥品工業) :日本的核准
  • Sym-004 (Symphogen) :初期的能人體臨床實驗上期待的結果
  • IMMU-130/Labetuzumab-SN-38 (Immunomedics):高抗腫瘤活動的ADC

第6章 大腸癌治療藥的研發產品線

  • CPX-1 (Celator Pharmaceuticals)
  • CT-011/Pidilizumab (CureTech)
  • Dabrafenib/Tafinlar (GSK)
  • E7820 (Eisai)
  • Entinostat (Syndax Pharmaceuticals)
  • Ganetespib (Synta Pharmaceuticals)
  • LGX818/Encorafenib (Novartis)
  • ABT-869/Linifanib (Abbott Laboratories)
  • MORAb-004/Ontuxizumab (Morphotek, Inc.)
  • Onartuzumab (Genentech)
  • JX-594 (SillaJen)
  • PF-05212384 (Pfizer)
  • Simtuzumab (Gilead)
  • Talaporfin Sodium (Aptocine, Light Sciences Oncology)
  • Tivantinib (ARQ 197; ArQule, 第一三共)
  • Tivozanib (Astellas Pharma/Aveo Pharmaceuticals)
  • Trametinib (Mekinist, GlaxoSmithKline)
  • Veliparib (ABT-888, AbbVie)
  • RG7221/ RO5520985/Vanucizumab (Roche)
  • BKM-120/Buparlisib (Novartis)
  • BYL-719/Alpelisib (Novartis)

第7章 大腸癌治療藥市場定性分析

  • 大腸癌治療藥市場SWOT分析
  • 大腸癌治療藥市場STEP分析

第8章 調查採訪

第9章 結論

  • 專利失效及生技仿製藥的影響
  • 美國:依然是最大的國家市場
  • APAC:預計顯示最快的成長
  • 大腸癌治療藥研發產品線:混亂但有幾個有前途的候補藥?
  • 結論

圖表

目錄
Product Code: PHA0077

Colorectal Cancer Drugs - Your New Guide to that Market, its R&D and Sales Potentials

Do you want to assess the future of colorectal cancer medicines? Visiongain's new report gives you revenue predictions for that industry from 2015, helping you stay ahead in knowledge and benefit your influence.

Our study shows you results, R&D trends, opportunities, interviews and revenue forecasts.

In that analysis you see predicted revenues to 2025 at overall world market, geographical and product level. You assess emerging trends, technologies and branded therapies. Explore the future of colorectal cancer drugs and their producers.

With our study, benefit your research, decisions, presentations and influence. Please read on now to discover how our new analysis can help your work.

Main ways Colorectal Cancer Drugs Industry and Market: Therapies, R&D and Forecasts 2015-2025 helps you

In these six main ways, visiongain's new analysis gives knowledge to make your work easier and faster, also benefiting your decisions and authority:

  • Revenue forecasting of the overall world market and 5 geographical submarkets - assess outlooks for development, production, marketing and sales, seeing what is possible
  • Nine leading drugs' revenues to 2025 - find sales potentials for top brands, seeing how they can compete and succeed
  • Profiles of leading companies - assess participants' results, portfolios, capabilities, deals and outlooks
  • R&D in colorectal cancer treatment - explore progress in research and development, finding technological, medical and commercial possibilities
  • Interviews with two other authorities - discover opinions to help you stay ahead in knowledge, finding what companies say and do
  • Analysis of what stimulates and restrains that pharma industry - assess challenges and opportunities, helping you gain advantages and succeed.

image1

What forces stimulate the market for colorectal cancer treating medicines?

In 2015 there exist at least 158 agents in clinical development for colorectal cancer. A large number of those products are in phase II development. Our report helps you understand opportunities in that field and how to use them.

As ageing populations increase, the incidence of cancer rises, leading to rising spending on cancer-treating medicines. That trend will continue. Are you ready for those commercial opportunities? Let our study guide you, showing what is possible.

Gain data found nowhere else, benefiting your influence on those anticancer medicines

Visiongain's study examines the colorectal cancer drugs market, using independent primary and secondary research. Gain discussions and data you find nowhere else.

In our new report you gain 35 charts, 29 tables and two research interviews to help you stay ahead in knowledge.

Forecasts for nine leading drugs - discover sales potentials

Our new investigation gives you revenue forecasts to 2025 for nine leading products for treating colorectal cancer:

  • Avastin (Roche)
  • Erbitux (BMS/Merck Serono)
  • Xeloda (Roche)
  • Vectibix (Amgen)
  • Stivarga (Bayer)
  • Eloxatin (Sanofi)
  • TS-1 (Taiho Pharmaceuticals)
  • Zaltrap (Sanofi)
  • Cyramza (Eli Lilly)

image2

In our work you also see profiles of leading companies and discussions of drugs in development. Our analysis explains activities and prospects of organisations developing, producing and marketing those therapies.

See what the future holds for products treating that disease. Our report explains, from 2015, pharma companies' commercial prospects. Explore what the future holds.

Geographical markets - where lie the best sales and growth potentials?

Our survey also shows forecasts to 2025 for these five regions, showing overall colorectal cancer drug revenues:

  • United States
  • European Union
  • Japan
  • APAC
  • Rest of the world.

That way you discover where revenue growth will occur in established pharma markets and in developing countries. Discover where the best prospects for sales and business expansion lie.

Get our independent study now - why wait and miss out?

Our new report shows you trends, results, R&D and revenue forecasts. There you gain data and discussions to assess the future of treating colorectal cancer.

That investigation's purpose is to benefit your knowledge and reputation for insight, increasing your chances of finding competitive advantages and succeeding.

Our study gives independent analysis, helping you stay ahead in competitive intelligence for cancer drug development, production and sales. Please get that report here now.

Table of Contents

1. Report Overview

  • 1.1 Overview of the World Market for Colorectal Cancer Drugs
  • 1.2 Why You Should Read This Report
  • 1.3 How This Study Delivers
  • 1.4 Main Questions Answered by this Analysis
  • 1.5 Who is this Report For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Some Associated Reports
  • 1.9 About Visiongain

2. Introduction to Colorectal Cancer and Treatments

  • 2.1 Pathophysiology of Colorectal Cancer
  • 2.2 Epidemiology of Colorectal Cancer
    • 2.2.1 Incidence - Increases with Age
    • 2.2.2 Mortality - Fourth-Leading Cause of Cancer Death
    • 2.2.3 Survival - Depends on Stage of Cancer
  • 2.3 Diagnosis - Benefits and Limitations
  • 2.4 Treatment and Staging
    • 2.4.1 Treatment Options
    • 2.4.2 Staging in Colorectal Cancers
    • 2.4.3 Treatment Depending on Stages

3. The World Colorectal Cancer Drugs Market, 2015-2025

  • 3.1 Global Colorectal Cancer Drugs Market Forecast 2015-2025
  • 3.2 Geographical Colorectal Cancer Drugs Market Forecasts 2015-2025
    • 3.2.1 The US Colorectal Cancer Drugs Market, 2015-2025
    • 3.2.1.1 The US Colorectal Cancer Drugs Market Forecast - Stagnant Growth
    • 3.2.2 The Japanese Colorectal Cancer Drugs Market, 2015-2025
    • 3.2.2.1 The Japanese Colorectal Cancer Drugs Market Forecast - High Price of Biosimilars Will Drive the Market
    • 3.2.3 The EU Colorectal Cancer Drugs Market, 2015-2025
      • 3.2.3.1 The EU Colorectal Cancer Drugs Market Forecast - Tough Regulatory Environment Will Slow Market Growth
    • 3.2.4 The APAC Countries Colorectal Cancer Drugs Market, 2015-2025
      • 3.2.4.1 The APAC Colorectal Cancer Drugs Market Forecast - Market Will Be Stimulated by Rising Incidence of Cancer Owing to Changes of Lifestyle
    • 3.2.5 Rest of the World Colorectal Cancer Drugs Market, 2015-2025
      • 3.2.5.1 Rest of the World Colorectal Cancer Drugs Market Forecast

4. The Top Colorectal Cancer Drugs: Revenue Forecasts, 2015-2025

  • 4.1 Avastin (Roche)
    • 4.1.1 Avastin Revenue Forecast - Leader of the Pack
    • 4.1.2 Roche
  • 4.2 Erbitux (BMS/Merck KGaA)
    • 4.2.1 Erbitux Revenue Forecast - Will its Revenue be Eroded by Biosimilars?
    • 4.2.2 BMS
    • 4.2.3 Merck KGaA
  • 4.3 Xeloda (Roche)
    • 4.3.1 Xeloda Revenue Forecast - Declining Sharply
  • 4.4 Vectibix (Amgen)
    • 4.4.1 Vectibix Revenue Forecast - Sales Will Grow During the First Half of the Forecast Period
    • 4.4.2 Amgen
  • 4.5 Eloxatin (Sanofi)
    • 4.5.1 Eloxatin Revenue Forecast - Declining Slowly
    • 4.5.2 Sanofi
  • 4.6 Zaltrap (Sanofi/Co-developed with Regeneron)
    • 4.6.1 Zaltrap Revenue Forecast - Sales Expected to Grow Significantly Until 2020
  • 4.7 Stivarga (Bayer)
    • 4.7.1 Stivarga Revenue Forecast - Positive Growth Trend
    • 4.7.2 Bayer
  • 4.8 TS-1 (Taiho Pharmaceuticals)
    • 4.8.1 TS-1 Revenue Forecast
    • 4.8.2 Taiho Pharmaceuticals
  • 4.9 Cyramza (Eli Lilly)
    • 4.9.1 Cyramza Revenue Forecast - Additional Approval for mCRC Will Drive Sales
    • 4.9.2 Eli Lilly

5. Emerging Therapies

  • 5.1 Lonsurf (Taiho Pharmaceuticals) - Approved in Japan
  • 5.2 Sym-004 (Symphogen) - Promising Results in Early Human Clinical Trials
  • 5.3 IMMU-130/Labetuzumab-SN-38 (Immunomedics) - ADC with High Anti-Tumour Activity

6. R&D Pipelines for Colorectal Cancer Treatment

  • 6.1 CPX-1 (Celator Pharmaceuticals) - Combination of Irinotecan HCl and Floxuridine
  • 6.2 CT-011/Pidilizumab (CureTech) - Binds to PD-1
  • 6.3 Dabrafenib/Tafinlar (GSK) - Inhibitor of B-Raf
  • 6.4 E7820 (Eisai) - Inhibits Integrin Alpha 2
  • 6.5 Entinostat (Syndax Pharmaceuticals) - Exhibits a Wide Range of Anti-Tumour Activity
  • 6.6 Ganetespib (Synta Pharmaceuticals) - Inhibits Hsp90
  • 6.7 LGX818/Encorafenib (Novartis) - Investigated in Several Trials
  • 6.8 ABT-869/Linifanib (Abbott Laboratories) - Inhibits VEGF and PDGF Receptors
  • 6.9 MORAb-004/Ontuxizumab (Morphotek, Inc.) - Targets Endosialin
  • 6.10 Onartuzumab (Genentech) - Targets the Protein MET
  • 6.11 JX-594 (SillaJen) - Oncolytic Virus
  • 6.12 PF-05212384 (Pfizer) - PI3K/mTOR Inhibitor
  • 6.13 Simtuzumab (Gilead) - Highly Selective for LOXL2
  • 6.14 Talaporfin Sodium (Aptocine, Light Sciences Oncology) - Water-Soluble Drug
  • 6.15 Tivantinib (ARQ 197; ArQule, Daiichi Sankyo) - An Option for EGFR-resistant MET-High mCRC Patients
  • 6.16 Tivozanib (Astellas Pharma/Aveo Pharmaceuticals) - Inhibits VEGF Receptors
  • 6.17 Trametinib (Mekinist, GlaxoSmithKline) - Blocks MEK1 and MEK2
  • 6.18 Veliparib (ABT-888, AbbVie) - An Oral PARP
  • 6.19 RG7221/ RO5520985/Vanucizumab (Roche) - Binds Ang2 and VEGF-A
  • 6.20 BKM-120/Buparlisib (Novartis) - Reduces Cellular Levels of Phosphorylated AKT
  • 6.21 BYL-719/Alpelisib (Novartis)

7. Qualitative Analysis of the Colorectal-Cancer Drugs Market 2015-2025

  • 7.1 SWOT Analysis of the Colorectal Cancer Drugs Market
    • 7.1.1 Strengths
      • 7.1.1.1 Rising Incidence of Cancer - Ageing Population
      • 7.1.1.2 Multiple Treatment Options Are Usually Needed
    • 7.1.2 Weaknesses
      • 7.1.2.1 The Challenges of Drug Development
      • 7.1.2.2 The Complex Nature of Cancer
    • 7.1.3 Opportunities in the Cancer Drugs Market
      • 7.1.3.1 The Advancement of Research
      • 7.1.3.2 A Shift Towards Personalisation
    • 7.1.4 Threats Facing the Cancer Drugs Market
      • 7.1.4.1 The Threat of Regulation
    • 7.2.1 Social Factors: The Cost of Living Longer
    • 7.2.2 Technological Developments: Making the Market Move Forward
    • 7.2.3 Economic Pressure: Treatment's Hefty Price Tag
    • 7.2.4 Political Issues: Governmental Involvement in Treatment

8. Research Interviews from Our Survey - 2015

  • 8.1 Dr. Philip M. Arlen, President and CEO, Precision Biologics, Inc., US
    • 8.1.1 Less Than 1% of Colonoscopies Screening Reveal Cancer
    • 8.1.2 Market Driver - New Drugs with Novel MoA and Favourable Safety Profile
    • 8.1.3 Ensituximab - Developed From a Tumour-Derived Cancer Vaccine
    • 8.1.4 60% of Patients with Colorectal and Pancreatic Cancer Express the Ensituximab Target
  • 8.2 Dr. John Beadle, CEO of PsiOxus Therapeutics, UK
    • 8.2.1 Significant Unmet Need - Effective Treatments for MSI Normal and MSI Low Patients
    • 8.2.2 Checkpoint Inhibitors - Work Well in MSI High Patients
    • 8.2.3 Enadenotucirev Remains Stable in Human Blood
    • 8.2.4 Enadenotucirev - Positioning in the Colorectal Cancer Market?

9. Conclusions of the Study

  • 9.1 Patent Expiries and the Impact of Biosimilars
  • 9.2 The US - Still the Largest National Market
  • 9.3 APAC - Will Show the Fastest Growth
  • 9.4 Colorectal Cancer Drugs R&D Pipeline - Crowded, but How Many Promising Drugs?
  • 9.5 Concluding Remarks

List of Tables

  • Table 1.1 Forecast Regional and National Colorectal Cancer Drugs Markets: Market Sizes ($bn), Annual Growth (%), CAGRs (%), 2015-2025
  • Table 2.1 Benefits and Limitations of Diagnostic Tests for Colorectal Cancer
  • Table 3.1 Global Colorectal Cancer Drug Market: Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 3.2 Leading National and Regional Colorectal Cancer Drug Markets: Revenue Forecasts ($bn), Annual Growth (%), CAGR (%) and Market Share (%), 2015-2025
  • Table 3.3 The US Colorectal Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 3.4 The Japanese Colorectal Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 3.5 The EU Colorectal Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 3.6 APAC Colorectal Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 3.7 RoW Colorectal Cancer Drugs Market Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.1 Top Colorectal Cancer Drugs: Revenue ($bn) and Market Share (%), 2014
  • Table 4.2 Top 9 Colorectal Cancer Drugs: Revenue Forecasts ($bn), CAGR (%) and Market Share (%), 2014, 2019, 2025
  • Table 4.3 Avastin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.4 Roche - Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
  • Table 4.5 Erbitux Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.6 Bristol-Myers Squibb - Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
  • Table 4.7 Merck KGaA- Revenue ($bn), Change (%) and Share (%), 2014
  • Table 4.8 Xeloda Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.9 Vectibix Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.10 Amgen - Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
  • Table 4.11 Eloxatin Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.12 Sanofi-Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
  • Table 4.13 Zaltrap Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.14 Stivarga Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.15 Bayer- Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
  • Table 4.16 TS-1 Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.17 Taiho Pharmaceutical- Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
  • Table 4.18 Cyramza Revenue Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2025
  • Table 4.19 Eli Lilly - Cancer Drugs by Revenue ($bn), Change (%) and Share (%), 2014
  • Table 7.1 Strengths, Weaknesses, Opportunities and Threats in the Colorectal Cancer Drugs Market, 2015
  • Table 7.2 Social, Technological, Economic and Political Analysis of the Colorectal Cancer Drugs Market, 2015

List of Figures

  • Figure 2.1 Current Standard Treatment Options for Metastatic Colorectal Cancer
  • Figure 3.1 Global Colorectal Cancer Drug Market: Revenue Forecast ($bn), 2015-2025
  • Figure 3.2 Global Colorectal Cancer Drugs Market: Drivers and Restraints, 2015-2025
  • Figure 3.3 The Leading National Colorectal Cancer Drugs Markets by Share of Global Market (%), 2014
  • Figure 3.4 The Leading National Colorectal Cancer Drugs Markets by Share of Global Market (%), 2019
  • Figure 3.5 The Leading National Colorectal Cancer Drugs Markets by Share of Global Market (%), 2025
  • Figure 3.6 Developed National Markets: Drivers and Restraints, 2015-2025
  • Figure 3.7 The US Colorectal Cancer Drugs Market Revenue Forecast ($bn), 2015-2025
  • Figure 3.8 The Japanese Colorectal Cancer Drugs Market Revenue Forecast ($bn), 2015-2025
  • Figure 3.9 The EU Colorectal Cancer Drugs Market Revenue Forecast ($bn), 2015-2025
  • Figure 3.10 APAC Colorectal Cancer Drugs Market Revenue Forecast ($bn), 2015-2025
  • Figure 3.11 Emerging National Markets: Drivers and Restraints, 2015-2025
  • Figure 3.12 RoW Colorectal Cancer Drugs Market Revenue Forecast ($bn), 2015-2025
  • Figure 4.1 Top 9 Colorectal Cancer Drugs: Market Share (%), 2014
  • Figure 4.2 Top 9 Colorectal Cancer Drugs: Market Share (%), 2019
  • Figure 4.3 Top 9 Colorectal-Cancer Drugs: Market Share (%), 2025
  • Figure 4.4 Avastin Revenue Share by Indication (%), 2014
  • Figure 4.5 Avastin Revenue Forecast ($bn), 2015-2025
  • Figure 4.6 Roche's Top Selling Cancer Drugs by Share of Company Revenue (%), 2014
  • Figure 4.7 Erbitux Revenue Forecast ($bn), 2015-2025
  • Figure 4.8 Bristol-Myers Squibb's Top Selling Cancer Drugs by Share of Company Revenue (%), 2014
  • Figure 4.9 Merck KGaA's Drug by Share of Company Revenue (%), 2014
  • Figure 4.10 Xeloda Revenue Forecast ($bn), 2015-2025
  • Figure 4.11 Vectibix Revenue Forecast ($bn), 2015-2025
  • Figure 4.12 Amgen's Top Selling Cancer Drugs by Share of Company Revenue (%), 2014
  • Figure 4.13 Eloxatin Revenue Forecast ($bn), 2015-2025
  • Figure 4.14 Sanofi's Top Selling Cancer Drugs by Share of Company Revenue (%), 2014
  • Figure 4.15 Zaltrap Revenue Forecast ($bn), 2015-2025
  • Figure 4.16 Stivarga Revenue Forecast ($bn), 2015-2025
  • Figure 4.17 Bayer's Top Selling Cancer Drugs by Share of Company Revenue (%), 2014
  • Figure 4.18 TS-1Revenue Forecast ($bn), 2015-2025
  • Figure 4.19 Taiho Pharmaceutical Top Selling Cancer Drugs by Share of Company Revenue (%), 2014
  • Figure 4.20 Cyramza Revenue Forecast ($bn), 2015-2025
  • Figure 4.21 Eli Lilly's Top Selling Cancer Drugs by Share of Company Revenue (%), 2014
  • Figure 9.1 Top 9 Colorectal Cancer Drugs: Revenues ($bn), 2014, 2019, 2025

Companies Listed

  • Abbott
  • AbbVie
  • Amgen
  • Astellas Pharmaceuticals
  • Aveo Pharmaceuticals
  • Bayer
  • BMS
  • Celator Pharmaceuticals
  • Chia Tai Tianqing Pharmaceutical Group
  • CureTech
  • Daiichi Sankyo
  • Eisai
  • Eli Lilly
  • EMEA
  • FDA
  • Genentech
  • Gilead
  • GSK
  • ImClone
  • Immunomedics
  • Jiangsu Hengrui Medicine
  • Light Sciences Oncology
  • Merck KGaA
  • Ministry of Health, Labour and Welfare Japan
  • Morphotek, Inc.
  • NHS
  • NICE
  • Novartis
  • Pfizer
  • Qilu Pharmaceutical
  • Regeneron
  • Roche
  • Sanofi
  • Sillajen
  • Symphogen
  • Syndax Pharmaceuticals
  • Synta Pharmaceuticals
  • Taiho Pharmaceuticals
Back to Top